



# Support for Clinics in Developing a Buprenorphine Treatment Program for Opioid Use Disorder

## Introduction

Although many primary care clinicians obtain a waiver from the DEA to prescribe buprenorphine for patients with Opioid Use Disorder (OUD), some clinicians work in settings that do not have clinical support systems in place that facilitate the use of these prescribing privileges.

The Six Building Blocks Program, in collaboration with Public Health – Seattle and King County, developed a resource to guide primary care organizations as they develop the clinic systems needed to support providers who wish to provide the critical service of treating patients with OUD. This resource provides key components that are either required for a health care system when providing buprenorphine treatment for OUD or are considered critical best practices. Buprenorphine treatment for OUD is evolving, and this document's recommendations reflect current thinking about how to support safe and effective medication treatment for OUD as of Spring 2020.

## Content

Developing a Buprenorphine Treatment Program for OUD in Primary Care addresses:

1. Staffing
2. Training
3. Billing
4. Supporting clinicians in providing consistent care for patients with OUD
5. Psychosocial treatment & recovery support services
6. Urine drug testing
7. Mitigating diversion
8. Administration

## Additional Support Available

- “How to get started with Bup” presentation for your clinic with follow-up support available as needed
- We are recruiting clinics for a Winter 2021 learning collaborative for practices implementing office-based treatment for OUD

## Contact Information

Please contact Ashley Johnson, MPH Research Scientist & Practice Facilitator, University of Washington Department [ashleyj5@uw.edu](mailto:ashleyj5@uw.edu) for more information.

SIX BUILDING BLOCKS: BUPRENORPHINE TREATMENT IN PRIMARY CARE SUPPORT OFFERINGS | VERSION 2020.11.17  
LICENSED UNDER A CREATIVE COMMONS BY-NC-ND 4.0 INTERNATIONAL LICENSE



*Funded by Agency for Healthcare Research & Quality (#R18HS023750, #HHSP2332015000131), Washington State Department of Health (CDC #5 NU17CE002734), National Institute on Drug Abuse (#UG1DA013714), and the Washington State's Olympic Communities of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of AHRQ, WA DOH, or NIDA. This resource has been developed by the University of Washington Department of Family Medicine, Kaiser Permanente Washington Health Research Institute and Public Health – Seattle & King County.*